Prevention of COPD exacerbations: How to conduct a clinical trial evaluating the benefits of inhaled steroids?;Prévention des exacerbations dans la BPCO: Réflexion sur la construction d'une étude clinique évaluant l'effet des corticostéroïdes inhalés

Revue des Maladies Respiratoires

Volumn 21, Issue 4 I, 2004, Pages 685-688

  Chabot, F ^a   Devillier, P ^b   Drugeon, H ^c   Dusser, D ^d   Fournier, M ^e   Gaillat, J ^f   Grouin, J M ^p   Housset, B ^g   Huchon, G ^h   Leophonte P ⁱ   Muir, J F ^j   Raffy, O ^k   Tonnel, A B ^l   Tremolieres, F ^m   Zuck P ⁿ   Attali, V ^o   Boucot, I ^o   Chemali Hudry, J ^o   Daniloski, M ^o  

^a CHU NANCY BRABOIS   (France)

^b HÔPITAL MAISON BLANCHE   (France)

^c HÔTEL DIEU   (France)

^d Hôpital Cochin ^*  (France)

^e BEAUJON HOSPITAL   (France)

^f Centre Hospitalier de la Region d'Annecy   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h HÔTEL DIEU   (France)

ⁱ SERVICE DE PNEUMOLOGIE   (France)

^j ROUEN UNIVERSITY HOSPITAL   (France)

^k Louis Pasteur Hospital   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m CH Mantes La Jolie   (France)

ⁿ Service de Pneumologie   (France)

^o Laboratoires GSK   (France)

^p CHRU da Lille ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MONEY; MORTALITY; PROPHYLAXIS; QUALITY OF LIFE; RESUSCITATION; RISK FACTOR;

EID: 7044274631     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8425(04)71408-4     Document Type: Conference Paper

References (16)

1. e congrès de pneumologie de langue française. Les recommandations sont disponibles sur le site Internet de la SPLF: www.splf.org.
2. Miravittles M, Murio C, Guerrero T, Gisbert R: Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123: 784-91.
3. Similowski T, Muir JF, Derenne JP: Les bronchopneumopathies chroniques obstructives. Collection Pathologie Science formation. John Libbey Eurotext, Paris, 1999. 236 p.
4. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-52.
5. Fournier M, Godard P, Housset B, Huchon G, Durand-Zaleski I, Detournay B, le groupe SCOPE: Impact socio-économique de la BPCO en France: étude SCOPE, Poster présenté au CPLF, 2003.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22.
7. Stoller JK: Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;346:988-94.
8. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J: On behalf of the International COPD Study Group: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-80.
9. Anthonisen NR, Manfreda J, Warren W, Hershfield S: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
10. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320: 1297-1303.
11. Kanner RE, Anthonisen NR, Connett JE: Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease - Results from the Lung Health Study. Am J Respir Crit Care Med 2001; 164: 358-64.
12. Wedzicha JA et al.: Exacerbations: etiology and pathophysiologic mechanisms. Chest 2002; 121: 136S-141S.
13. The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.
14. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: for the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-53.
15. Alsaeedi A, Sin DD, McAlister FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65.
16. Jarad NA, Wedzicha JA, Burge PS, Calverley: PMA for the ISOLDE Study Group. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999; 93: 161-6.